Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have a clinical diagnosis to apply the conservative medication for chronic hepatitis C.~2. Serum alanine aminotransferase levels measured at 4-week before the initiation of treatment must be over 61 IU/mL.~3. Subject's age must be 20 years or older.~Exclusion Criteria:~1. Subject who received a treatment of antiviral agents (interferon) within 20 weeks before the start of 8-week observation period~2. Subject who received a treatment of corticosteroids, immunosuppressive drugs, glycyrrhizic acid, cholestyramine or other drugs which could interfere with hepatic function during 8-week observation period.~3. Subject with decompensated cirrhosis~4. Subject infecting with other hepatic virus~5. Subject receiving a treatment for autoimmune disease, alcohol or drug-induced hepatic disorder, neoplasia, hepato-cholangiolar disease, fulminant hepatitis or peptic ulcer~6. Subject who require hospitalization for complications of the heart, kidney or pancreas~7. Pregnancy~8. Alcoholics~9. Alcohol intake more than 27 ml/day~10. Subject who involved in other clinical trial within 4 weeks before the start of observation period~11. Subject with a history of sensitivity to ursodeoxycholic acid or bile acid-products

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ursodeoxycholic acid 150mg / day (Type: EXPERIMENTAL): None
- Ursodeoxycholic acid 600mg / day (Type: EXPERIMENTAL): None
- Ursodeoxycholic acid 900mg / day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).